BioSpace News Archive

BIOQUAL, Inc., Announces Creation of the Role of Chief Scientific Officer and Appointment of Hanne Andersen Elyard, PhD, As the Initial Chief Scientific Officer.

Sesen Bio today reported operating results for the first quarter ended March 31, 2022.

Celsion Corporation announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs.

Albireo Pharma, Inc. today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on May 16, 2022, to provide a business update and review the company’s financial results for the quarter ended March 31, 2022.

Alaunos Therapeutics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets.

The Diabetes Research Institute along with the Diabetes Research Institute Foundation Canada and Alberta Diabetes Institute at the University of Alberta, Canada’s largest stand-alone research facility dedicated to finding a cure of diabetes, announced the launch of a research partnership to advance efforts to find a cure for diabetes.

Longeveron Inc. announced the resignation of Chief Executive Officer Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2022 and provided an update on recent corporate highlights.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2022 financial results and business updates.